The market for Laboratory proficiency testing is expected to witness significant growth during the forecast period. PT forms an essential precondition for operational excellence and accreditation in several industries. This is one of the major factors driving the growth of the laboratory proficiency testing market globally. Also, the increasing number of laboratory accreditations, stringent safety and quality regulations for food and pharmaceutical products and the increasing focus on water testing are the other major factors supporting market growth. However, the requirement of high capital investments for accurate and sensitive testing is expected to restrain the growth of this market during the forecast period.

The global Laboratory proficiency testing market is projected to reach USD 1.4 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 6.4%.

With proficiency testing being a mandatory procedure to be undertaken by laboratories functioning in different industries which are under regulation by organizations such as the CLIA, APLAC, and CLSI,

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144227949

The prominent players in the laboratory proficiency testing market are LGC Limited (UK), American Proficiency Institute (US), College of American Pathologists (US), Bio-Rad Laboratories (US), Randox Laboratories (UK), Merck (Germany), Fapas (Fera Science Ltd.) (UK), Waters Corporation (US), Weqas (UK), AOAC INTERNATIONAL (US), BIPEA (France), NSI Lab Solutions (US), Absolute Solutions (US), Trilogy Analytical Laboratories (US), Advanced Analytical Solutions (US), American Industrial Hygiene Association (US), Matrix Sciences (US), Aashvi Proficiency Testing & Analytical Services (India), and Global Proficiency (New Zealand).

LGC Limited (UK) is the leading player in the laboratory proficiency testing market. The company provides a wide range of proficiency testing solutions under its flagship brand–AXIO. The company provides proficiency testing schemes with support across a global network to 13,000 laboratories in more than 160 countries, which conducts approximately 2,000 proficiency tests every year. The company is mainly focusing on organic strategies such as product launches to maintain and improve its share in the market. For instance, in April 2020, the company launched a proficiency testing (PT) service for the detection of SARS-CoV-2 (COVID 19) by nucleic acid amplification testing. Also, in January 2018, the company launched human blood-sirolimus (ERM-DA111a), an immunosuppressant certified reference material, and Triiodothyronine Kit, calibration verification kit. LGC Limited also pursues the strategy of expansions. In this regard, in June 2021, the company announced the development of a new business group to provide supply chain assurance solutions for the manufacturing, laboratory, ingredients, and nutritional supplements sectors.

College of American Pathologists held the second position in the laboratory proficiency testing market. In 2020, more than 25,000 laboratories enrolled in proficiency testing (PT) programs and the CAP accredited more than 5,000 laboratories worldwide. Over 25,000 laboratories are using CAP proficiency testing programs across the globe. The company has a strong focus on enhancing its PT service portfolio in the proficiency testing market through both organic and inorganic growth strategies, such as product launches and investments. For instance, in April 2020, the company launched a new proficiency testing (PT) program for the detection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). The company also continued to fund programs that meet the members’ top needs. In 2020, the company invested USD 10.2 million into high-quality, practical learning and member conferences. Throughout the COVID-19 pandemic, the company has been working to help navigate the unique complexity and compliance requirements of SARS-CoV-2 testing along with everyday high-quality laboratory management and testing for patients.

Request Sample Pages:-https://www.marketsandmarkets.com/requestsampleNew.asp?id=144227949

Bio-Rad Laboratories is one of the leading players in the laboratory proficiency testing market. The company supplies more than 3,000 products covering more than 300 clinical diagnostic tests. It has a wide range of product offerings for the Life Science and Clinical Diagnostics segments. The Clinical Diagnostics segment observed a decrease of 7.6% in revenue in 2020 as compared to 2019. Although there were a few fluctuations in demand, the overall sales were largely unaffected. With its strong geographic presence and wide distribution network, Bio-Rad Laboratories has established itself as a leader in the global market. The company offers fully accredited PT/EQA programs in chemistry (serum and urine), immunoassay, therapeutic drugs, and hematology. The EQAS program is fully accredited with ISO/IEC 17043:2010.